<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671836</url>
  </required_header>
  <id_info>
    <org_study_id>20-0773</org_study_id>
    <nct_id>NCT04671836</nct_id>
  </id_info>
  <brief_title>Lorazepam Effects on Neuroimaging Measures</brief_title>
  <official_title>Lorazepam Effects on Neuroimaging Measures: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This within-subject, double blind, randomized controlled study will investigate the effects&#xD;
      of a widely used benzodiazepine (BZD), lorazepam, on various neuroimaging measures. The&#xD;
      investigators will be assessing the relationship of lorazepam to resting state functional&#xD;
      connectivity and other neuroimaging measures. Specifically, the investigators will be using a&#xD;
      pre-identified metric, the striatal connectivity index (SCI), (Sarpal et al. 2015, 2016), a&#xD;
      prognostic biomarker of treatment response assessing the connectivity between regions of the&#xD;
      striatum and the cortex. The investigators hypothesize that lorazepam administration will be&#xD;
      associated with greater SCI values compared with placebo administration; consistent with&#xD;
      previous work suggesting short-acting benzodiazepines increase functional connectivity across&#xD;
      brain networks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To understand the impact of lorazepam on functional connectivity measures collected using resting state functional magnetic imaging (rs-fMRI).</measure>
    <time_frame>2 weeks</time_frame>
    <description>SCI, a parameter that captures the connectivity between the stratum and the cortex, is a primary candidate for a prognostic biomarker that may guide individual treatment. Exploratory functional connectivity analyses between other brain regions will be conducted as well.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The goal is to study the impact of lorazepam on glutamate, glutamine and GABA in the striatum.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Metabolite concentrations measured in parts per million (ppm) for Glutamate, glutamine and GABA; obtained with Magnetic Resonance Spectroscopy (MRS).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lorazepam</condition>
  <condition>Neuroimaging</condition>
  <arm_group>
    <arm_group_label>Lorazepam first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm comprises of participants who were randomized to receive lorazepam 1 mg prior to the first MRI scan and then placebo on the second MRI scan a week later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm comprises of participants who were randomized to receive placebo prior to the first MRI scan and then lorazepam 1 mg orally prior to the second MRI scan a week later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam 1Mg Tablet</intervention_name>
    <description>1 mg, white, five-sided (shield shape) tablet with a raised &quot;A&quot; on one side and &quot;BPI&quot; and &quot;64&quot; impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.&#xD;
The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI.</description>
    <arm_group_label>Lorazepam first</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.</description>
    <arm_group_label>Lorazepam first</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible to participate in this study, an individual must meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, aged 18-40&#xD;
&#xD;
          4. In general good health as evidenced by medical history&#xD;
&#xD;
          5. Ability to take oral medication and be willing to adhere to the study medication&#xD;
             regimen&#xD;
&#xD;
          6. For women of reproductive potential, negative pregnancy test and agreement to use a&#xD;
             medically accepted birth control method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        An individual who meets any of the following criteria will be excluded from participation&#xD;
        in this study:&#xD;
&#xD;
          1. Pregnancy or lactation&#xD;
&#xD;
          2. Contraindications to MR imaging (i.e. pacemaker)&#xD;
&#xD;
          3. Known allergic reactions to components of the lorazepam&#xD;
&#xD;
          4. Current smoker or tobacco use&#xD;
&#xD;
          5. Concurrent use of any psychotropic medications, anticonvulsants, opioids or any other&#xD;
             medication with effects on the CNS.&#xD;
&#xD;
          6. Acute narrow-angle glaucoma&#xD;
&#xD;
          7. Current or past history of a substance use disorder and/or a positive urine toxicology&#xD;
             test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan A Gallego, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan A Gallego, MD</last_name>
    <phone>718-470-4588</phone>
    <email>jgallego@northwell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sana A Ali, BA</last_name>
    <phone>718-470-8887</phone>
    <email>sali17@northwell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Zucker Hillside Hospital</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sarpal DK, Argyelan M, Robinson DG, Szeszko PR, Karlsgodt KH, John M, Weissman N, Gallego JA, Kane JM, Lencz T, Malhotra AK. Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment. Am J Psychiatry. 2016 Jan;173(1):69-77. doi: 10.1176/appi.ajp.2015.14121571. Epub 2015 Aug 28.</citation>
    <PMID>26315980</PMID>
  </results_reference>
  <results_reference>
    <citation>Sarpal DK, Robinson DG, Lencz T, Argyelan M, Ikuta T, Karlsgodt K, Gallego JA, Kane JM, Szeszko PR, Malhotra AK. Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. JAMA Psychiatry. 2015 Jan;72(1):5-13. doi: 10.1001/jamapsychiatry.2014.1734.</citation>
    <PMID>25372846</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Juan Gallego Angel</investigator_full_name>
    <investigator_title>Assistant Investigator</investigator_title>
  </responsible_party>
  <keyword>lorazepam</keyword>
  <keyword>functional connectivity</keyword>
  <keyword>spectroscopy</keyword>
  <keyword>healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

